5j74 - Revision history

OCA at 10:51, 6 September 2023

OCA — Wed, 06 Sep 2023 10:51:46 GMT

←Older revision		Revision as of 10:51, 6 September 2023
Line 3:		Line 3:
	<StructureSection load='5j74' size='340' side='right'caption='[[5j74]], [[Resolution\|resolution]] 2.70Å' scene=''>		<StructureSection load='5j74' size='340' side='right'caption='[[5j74]], [[Resolution\|resolution]] 2.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5j74]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5J74 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5J74 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5j74]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5J74 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5J74 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.7Å</td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5j75\|5j75]]~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5j74 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5j74 OCA], [~~http~~://pdbe.org/5j74 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5j74 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5j74 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5j74 ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5j74 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5j74 OCA], [https://pdbe.org/5j74 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5j74 RCSB], [https://www.ebi.ac.uk/pdbsum/5j74 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5j74 ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 21:		Line 21:
	*[[Antibody 3D structures\|Antibody 3D structures]]		*[[Antibody 3D structures\|Antibody 3D structures]]
	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]		*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
		+	*[[3D structures of human antibody\|3D structures of human antibody]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Stanfield~~, R L~~]]	+	[[Category: Stanfield RL]]
-	[[Category: Wilson~~, I A~~]]	+	[[Category: Wilson IA]]
-	[[Category: Wu, Y]]	+	[[Category: Wu Y]]
-	~~[[Category: Fluorogen activating protein drug discovery biosensor protein trafficking]]~~	+
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Protein binding~~]]	+

OCA at 07:39, 27 November 2019

OCA — Wed, 27 Nov 2019 07:39:01 GMT

←Older revision		Revision as of 07:39, 27 November 2019
Line 1:		Line 1:

	==Fluorogen activating protein AM2.2 in complex with TO1-2p==		==Fluorogen activating protein AM2.2 in complex with TO1-2p==
-	<StructureSection load='5j74' size='340' side='right' caption='[[5j74]], [[Resolution\|resolution]] 2.70Å' scene=''>	+	<StructureSection load='5j74' size='340' side='right'caption='[[5j74]], [[Resolution\|resolution]] 2.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5j74]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5J74 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5J74 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5j74]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5J74 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5J74 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5j75\|5j75]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5j75\|5j75]]</td></tr>
Line 17:		Line 17:
	</div>		</div>
	<div class="pdbe-citations 5j74" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5j74" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
		+	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Stanfield, R L]]		[[Category: Stanfield, R L]]
	[[Category: Wilson, I A]]		[[Category: Wilson, I A]]

OCA at 10:48, 13 September 2017

OCA — Wed, 13 Sep 2017 10:48:19 GMT

←Older revision		Revision as of 10:48, 13 September 2017
Line 6:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5j75\|5j75]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5j75\|5j75]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5j74 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5j74 OCA], [http://pdbe.org/5j74 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5j74 RCSB], [http://www.ebi.ac.uk/pdbsum/5j74 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5j74 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5j74 OCA], [http://pdbe.org/5j74 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5j74 RCSB], [http://www.ebi.ac.uk/pdbsum/5j74 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5j74 ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">

OCA at 23:04, 1 June 2016

OCA — Wed, 01 Jun 2016 23:04:01 GMT

←Older revision		Revision as of 23:04, 1 June 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5j74 is ~~ON HOLD~~	+	==Fluorogen activating protein AM2.2 in complex with TO1-2p==
		+	<StructureSection load='5j74' size='340' side='right' caption='[[5j74]], [[Resolution\|resolution]] 2.70Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5j74]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5J74 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5J74 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6GN:1-(17-AMINO-5,8-DIOXO-12,15-DIOXA-4,9-DIAZAHEPTADECAN-1-YL)-4-{[3-(3-SULFOPROPYL)-1,3-BENZOTHIAZOL-3-IUM-2-YL]METHYL}QUINOLIN-1-IUM'>6GN</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5j75\|5j75]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5j74 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5j74 OCA], [http://pdbe.org/5j74 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5j74 RCSB], [http://www.ebi.ac.uk/pdbsum/5j74 PDBsum]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	A new class of biosensors, fluorogen activating proteins (FAPs), has been successfully used to track receptor trafficking in live cells. Unlike the traditional fluorescent proteins (FPs), FAPs do not fluoresce unless bound to their specific small-molecule fluorogens, and thus FAP-based assays are highly sensitive. Application of the FAP-based assay for protein trafficking in high-throughput flow cytometry resulted in the discovery of a new class of compounds that interferes with the binding between fluorogens and FAP, thus blocking the fluorescence signal. These compounds are high-affinity, nonfluorescent analogs of fluorogens with little or no toxicity to the tested cells and no apparent interference with the normal function of FAP-tagged receptors. The most potent compound among these, N,4-dimethyl-N-(2-oxo-2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)benzenesulfonamide (ML342), has been investigated in detail. X-ray crystallographic analysis revealed that ML342 competes with the fluorogen, sulfonated thiazole orange coupled to diethylene glycol diamine (TO1-2p), for the same binding site on a FAP, AM2.2. Kinetic analysis shows that the FAP-fluorogen interaction is more complex than a homogeneous one-site binding process, with multiple conformational states of the fluorogen and/or the FAP, and possible dimerization of the FAP moiety involved in the process.

-	~~Authors:~~ Stanfield, ~~R.L.~~, ~~Wilson~~, I.A., Wu, Y.	+	Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair.,Wu Y, Stauffer SR, Stanfield RL, Tapia PH, Ursu O, Fisher GW, Szent-Gyorgyi C, Evangelisti A, Waller A, Strouse JJ, Carter MB, Bologa C, Gouveia K, Poslusney M, Waggoner AS, Lindsley CW, Jarvik JW, Sklar LA J Biomol Screen. 2016 Jan;21(1):74-87. doi: 10.1177/1087057115609145. Epub 2015, Oct 6. PMID:26442911<ref>PMID:26442911</ref>

-	~~Description: Fluorogen activating protein AM2~~.~~2 in complex with TO1~~-2p	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5j74" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Stanfield, R L]]
		+	[[Category: Wilson, I A]]
	[[Category: Wu, Y]]		[[Category: Wu, Y]]
-	[[Category: ~~Stanfield, R.L~~]]	+	[[Category: Fluorogen activating protein drug discovery biosensor protein trafficking]]
-	[[Category: ~~Wilson, I.A~~]]	+	[[Category: Immune system]]
		+	[[Category: Protein binding]]

OCA: Protected "5j74" [edit=sysop:move=sysop]

OCA — Wed, 11 May 2016 01:36:00 GMT

Protected "5j74" [edit=sysop:move=sysop]

←Older revision

Revision as of 01:36, 11 May 2016

OCA: New page: '''Unreleased structure''' The entry 5j74 is ON HOLD Authors: Stanfield, R.L., Wilson, I.A., Wu, Y. Description: Fluorogen activating protein AM2.2 in complex with TO1-2p [[Category: U...

OCA — Wed, 11 May 2016 01:35:58 GMT

New page: '''Unreleased structure''' The entry 5j74 is ON HOLD Authors: Stanfield, R.L., Wilson, I.A., Wu, Y. Description: Fluorogen activating protein AM2.2 in complex with TO1-2p [[Category: U...

New page

'''Unreleased structure'''

The entry 5j74 is ON HOLD

Authors: Stanfield, R.L., Wilson, I.A., Wu, Y.

Description: Fluorogen activating protein AM2.2 in complex with TO1-2p
[[Category: Unreleased Structures]]
[[Category: Wu, Y]]
[[Category: Stanfield, R.L]]
[[Category: Wilson, I.A]]